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Ireland has the world’s highest incidence of Cystic Fibrosis at approximately 1 in
1400 [1,2]. CF was integrated into the newborn bloodspot screening programme
in July 2011 using an IRT/ DNA analysis strategy. Babies with a blood IRT above
the 99th percentile and with one or two CFTR mutations detected are referred for
sweat testing.
The anticipated number of CF cases (54) and carriers (94), were calculated based
on the birth rates from the 2008 census and assuming a 2.5-fold enrichment of
carriers within the top IRT percentile.
During the ﬁrst 6 months of the programme, 37,435 babies were screened and
391 (1.0%) were referred for DNA testing. 16 CF cases (all with 2 mutations and
conﬁrmed by sweat testing) and 35 unaffected carriers were detected, giving an
annualised CF incidence of 1 in 2340.
Just 59% of the predicted number of CF cases (p = 0.038) and 74% of the predicted
number of unaffected carriers (p = 0.014) were detected. Data from 2010 indicates
that 25% of newborns in Ireland had non-Irish mothers. When the expected numbers
were recalculated, based on the CF incidence in the nationality of the mother (and
assuming the father has the same nationality), 72% of expected cases (p = 0.187)
and 100% of expected unaffected carriers were detected. The apparent reduction in
the number of cases and the changing incidence of CF in Ireland may reﬂect the
signiﬁcant increase in immigration (particularly from Eastern Europe) since 2004,
after the published CF incidence ﬁgures were calculated.
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Inclusion criteria of subjects in CF registries can vary over time and between
countries which may introduce bias when data are used for benchmarking.
We explored whether the subjects included in 2009 in 3 national CF registries
[Belgium (BE), The Netherlands (NL), France (FR)] fulﬁlled strict diagnostic
criteria: sweat test (ST) chloride >60 mEq/L and/or 2 disease causing CFTR
mutations identiﬁed as speciﬁed in the CFTR2 project (access via courtesy of
P Sosnay and G Cutting).
Country BE NL F
Total n 1129 1299 5640
n (%) diagnostic not documented 117 (10.3%) 188 (14.5%) 593 (10.5%)
. n (%) <2 CF dcm & no ST 33 (2.9%) 178 (13.7%) 339 (6.0%)
. n (%) <2 CF dcm & ST Cl <60 84 (7.4%) 10 (0.8%) 254 (4.5%)
.. n (%) no CF dcm & ST Cl <30 4 (0.3%) 1 (0.1%) 10 (0.2%)
F508del homozygotes (%) 45.9% 55.3% 43.6%
PS (%) 13.2% 14.2% 17.0%
median (IQR) age (yr) 18.8 (10.2–28.9) 18.0 (9.8–29.6) 16.0 (8−25)
dcm: disease causing mutations.
Diagnostic is not documented in at least 10% of subjects reported in these 3 CF
registries; not reported ST data accounts for 28 to 95% of these cases. No CFTR
mutations reported plus ST chloride below 30mmol/L occurs, but rarely (0.1−0.3%).
A common and strict case deﬁnition of who should be reported and/or analyzed in
CF registries is needed. Efforts should be done to increase accuracy in CF registries
e.g. speciﬁcally documenting all tests conﬁrming the CF diagnosis.
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Introduction: We outline a novel approach for the joint modelling of lung function
and survival in the UK Cystic Fibrosis Population. The aim is to quantify how
aspects of an individual cystic ﬁbrosis patient’s longitudinal proﬁle of %FEV1 are
related to their survival prognosis.
Methods: We use the UK CF registry and apply recently developed methodology
using open-source software (R) for the joint analysis of repeated measurements and
time-to-event outcomes. These methods allow examination of association between
%FEV1 and covariates such as sex, genotype and screening status, whilst allowing
for correlation within patients, trends over time and potentially informative missing
values. Key methodological challenges relate to accommodating cohort effects, and
biased entry to registry cohorts.
Results: The dataset includes around 46,000 measures of %FEV1 on 8,000 patients
seen between 1999 and 2010, and captures 1000 deaths. In our preliminary analysis
stratiﬁed by birth cohort: For people born in 1975 to 1979, all other things being
equal, a 10% higher level of %FEV1 is associated with a halving of the concurrent
hazard for death (HR 0.44 CI 0.38 to 0.50). People with a stable %FEV1, compared
to a 1% per year decline, have a 10% lower hazard of death for every year that
passes (HR 0.9 CI 0.89 to 0.92).
Conclusions: We apply a novel modelling approach to quantify how longitudinal
changes in lung function are related to survival. Both an increased rate of decline in
lung function, and a decreased absolute level of lung function are associated with
an increased risk of death.
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Although many risk factors are postulated as important in the progression of CF
lung disease, their relative impact over time has been uncertain. The epidemiologic
component of the 27 year old Wisconsin Newborn Screening Project afforded us
the opportunity to evaluate the signiﬁcance of 18 potential determinants. For this
study, we combined the 132 enrolled subjects of the Screened and Control cohorts
to increase power since group comparisons revealed no differences in pulmonary
outcomes after adjustment for confounders. Prospective, systematic assessments
were performed longitudinally beginning at diagnosis and continuing throughout
childhood, including 1579 chest radiographs, scored by the Wisconsin chest xray
(WCXR) method, and 1792 pulmonary function tests. Examining 6 intrinsic and
12 extrinsic risk factors and using mainly GEE analysis with adjustments for
age, we found that the strongest associations with worsening WCXR scores were
genotype, mucoid Pseudomonas aeruginosa (MPa) (both its presence and duration),
malnutrition (using height percentile <10th), and hospitalizations (reﬂecting exac-
erbations). The longitudinal comparisons with FEV-1 values generally conﬁrmed
the signiﬁcance of these four factors but the decreases over time were relatively
modest compared to the lung disease progression evident in the chest radiographs.
In contrast to MPa, neither Staphylococcus aureus nor non-mucoid Pa showed a
signiﬁcant association. In addition, meconium ileus and gender were not signiﬁcant.
Our observations support the view that aside from genotype extrinsic factors that
can be modiﬁed are the major determinants of lung disease progression in children
with CF.
